16:34 , Sep 21, 2018 |  BC Week In Review  |  Company News

Servier declines rights to GeNeuro's GNbAC1

Servier (Neuilly-sur-Seine, France) declined to exercise an option to license rights outside the U.S. and Japan from GeNeuro S.A. (Euronext:GNRO) to develop and commercialize GNbAC1 to treat multiple sclerosis. The companies said Servier's decision was...
17:15 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

GeNeuro reports 12-month Phase IIb data for RRMS candidate

GeNeuro S.A. (Euronext:GNRO) and Servier (Suresnes, France) reported 12-month data from the double-blind, European Phase IIb CHANGE-MS trial in 270 patients with relapsing-remitting multiple sclerosis (RRMS). Patients received placebo or one of three doses of...
20:16 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

GeNeuro's GNbAC1 misses in Phase IIb for RRMS

GeNeuro S.A. (Euronext:GNRO) and Servier (Neuilly-sur-Seine, France) reported data from the 12-month Phase IIb CHANGE-MS trial in 270 patients with relapsing-remitting multiple sclerosis (RRMS) showing that once-monthly IV GNbAC1 missed the primary endpoint of reducing...
15:01 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

GeNeuro starts Phase IIa of GNbAC1 in Type I diabetes

In April, GeNeuro S.A. (Euronext:GNRO) began a Phase IIa trial to evaluate GNbAC1 in about 60 recently diagnosed adults with Type I diabetes. The placebo-controlled, Australian trial will evaluate safety as the primary endpoint. Secondary endpoints...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc.'s anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical and...
01:33 , Apr 19, 2016 |  BC Extra  |  Financial News

GeNeuro raises EUR 33 million in IPO

GeNeuro S.A. (Euronext:GNRO) raised EUR 33 million ($37.3 million) through the sale of 2.5 million shares at EUR 13 in an IPO. Trading of its shares is expected to begin Tuesday on Euronext. GeNeuro's GNbAC1...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

GNbAC1: Phase IIb started

GeNeuro began the placebo-controlled, European Phase IIb CHANGE-MS trial to evaluate GNbAC1 in 260 patients. In 2014, GeNeuro granted Servier (Neuilly-sur-Seine, France) an option to license exclusive rights to develop and commercialize GNbAC1 worldwide,...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

GeNeuro, Servier deal

Servier exercised its option under a 2014 deal and will become a minority shareholder in GeNeuro. The exercise follows the start of a Phase IIb trial evaluating GNbAC1 to treat relapsing-remitting multiple sclerosis (RRMS)....
07:00 , Oct 15, 2015 |  BC Innovations  |  Targets & Mechanisms

ART for ALS

Although GeNeuro S.A. has made the case for human endogenous retroviruses (HERVs) in multiple sclerosis, it's been a slow road to establish a solid link for the viruses to other diseases. An NIH group has...
07:00 , Jun 11, 2015 |  BC Innovations  |  Targets & Mechanisms

GeNeuro goes retro

GeNeuro S.A. put human endogenous retroviruses on the map as drug targets for multiple sclerosis, but new data point to a pathological role for the viruses in a much broader spectrum of diseases. Now GeNeuro...